Founded in 2020, Yemaachi Biotech focuses on diversifying precision oncology by creating a first‑of‑its‑kind Pan‑African genomic and clinical knowledge base and research platform. The company combines immunogenomics, bioinformatics and deep‑learning/AI to develop novel diagnostics and identify therapeutic targets. Yemaachi also offers clinical testing services, including NGS‑based screening and diagnostic testing optimized for local populations. It has launched the AMBER Study with Lucence to characterize breast cancer genomics in women of African descent using liquid biopsy and introduced the at‑home Sheba HPV Test in Ghana. Yemaachi is building deep clinical partnerships across Africa to support research, product development and broader access to precision oncology. Financially, the company closed a $3 million seed round and was named a recipient of a $1 million grant through the Calestous Juma Science Leadership Fellowship awarded by the Bill & Melinda Gates Foundation.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2022